Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.

Animals Antibodies, Neutralizing / chemistry CRISPR-Cas Systems Camelids, New World / genetics Female Gene Editing Humans Male Mice Mice, Inbred C57BL Models, Molecular Mutation Neutralization Tests SARS-CoV-2 / chemistry Single-Domain Antibodies / chemistry Somatic Hypermutation, Immunoglobulin / genetics Spike Glycoprotein, Coronavirus / chemistry

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
07 2021
Historique:
received: 04 03 2021
accepted: 27 05 2021
pubmed: 8 6 2021
medline: 10 7 2021
entrez: 7 6 2021
Statut: ppublish

Résumé

Since the start of the COVID-19 pandemic, SARS-CoV-2 has caused millions of deaths worldwide. Although a number of vaccines have been deployed, the continual evolution of the receptor-binding domain (RBD) of the virus has challenged their efficacy. In particular, the emerging variants B.1.1.7, B.1.351 and P.1 (first detected in the UK, South Africa and Brazil, respectively) have compromised the efficacy of sera from patients who have recovered from COVID-19 and immunotherapies that have received emergency use authorization

Identifiants

DOI: 10.1038/s41586-021-03676-z PMID: 34098567 PMC: PMC8260353
pubmed: 34098567
doi: 10.1038/s41586-021-03676-z
pii: 10.1038/s41586-021-03676-z
pmc: PMC8260353
doi:

Substances chimiques

Antibodies, Neutralizing 0
Single-Domain Antibodies 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

278-282

Subventions

Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States

Commentaires et corrections

Type : UpdateOf
Type : CommentIn

Références

Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616–622 (2021).
doi: 10.1038/s41586-021-03324-6 pubmed: 33567448 pmcid: 8503938
Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135 (2021).
doi: 10.1038/s41586-021-03398-2 pubmed: 33684923
Wu, K. et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. Preprint at https://doi.org/10.1101/2021.01.25.427948 (2021).
Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775–797 (2013).
doi: 10.1146/annurev-biochem-063011-092449 pubmed: 23495938
Muyldermans, S. Applications of nanobodies. Annu. Rev. Anim. Biosci. 9, 401–421 (2021).
doi: 10.1146/annurev-animal-021419-083831 pubmed: 33233943
Scully, M. et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N. Engl. J. Med. 380, 335–346 (2019).
doi: 10.1056/NEJMoa1806311 pubmed: 30625070
Hussen, J. & Schuberth, H. J. Recent advances in camel immunology. Front. Immunol. 11, 614150 (2021).
doi: 10.3389/fimmu.2020.614150 pubmed: 33569060 pmcid: 7868527
Kong, R. et al. Antibody lineages with vaccine-induced antigen-binding hotspots develop broad HIV neutralization. Cell 178, 567–584 (2019).
doi: 10.1016/j.cell.2019.06.030 pubmed: 31348886 pmcid: 6755680
Pham, P., Bransteitter, R., Petruska, J. & Goodman, M. F. Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature 424, 103–107 (2003).
doi: 10.1038/nature01760 pubmed: 12819663
Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501–1505 (2020).
doi: 10.1126/science.abd0826 pubmed: 32703906
Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437–442 (2020).
doi: 10.1038/s41586-020-2456-9 pubmed: 32555388 pmcid: 7442695
Schoof, M. et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science 370, 1473–1479 (2020).
pubmed: 33154106 pmcid: 7857409
Xiang, Y. et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science 370, 1479–1484 (2020).
pubmed: 33154108 pmcid: 7857400
Saelens, X. & Schepens, B. Single-domain antibodies make a difference. Science 371, 681–682 (2021).
doi: 10.1126/science.abg2294 pubmed: 33574203
Kupferschmidt, K. Fast-spreading U.K. virus variant raises alarms. Science 371, 9–10 (2021).
doi: 10.1126/science.371.6524.9 pubmed: 33384355
Faria, N. R. et al. Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. Preprint at https://doi.org/10.1101/2021.02.26.21252554 (2021).
Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 217, e20201181 (2020).
doi: 10.1084/jem.20201181 pubmed: 32692348 pmcid: 7372514
Benton, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327–330 (2020).
doi: 10.1038/s41586-020-2772-0 pubmed: 32942285 pmcid: 7116727
Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220 (2020).
doi: 10.1038/s41586-020-2180-5 pubmed: 32225176
Zhou, T. et al. Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains. Cell Host Microbe 28, 867–879 (2020).
doi: 10.1016/j.chom.2020.11.004 pubmed: 33271067 pmcid: 7670890
Wrapp, D. et al. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell 181, 1004–1015 (2020).
doi: 10.1016/j.cell.2020.04.031 pubmed: 32375025 pmcid: 7199733
Koenig, P. A. et al. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science 371, eabe6230 (2021).
doi: 10.1126/science.abe6230 pubmed: 33436526 pmcid: 7932109
Janssens, R. et al. Generation of heavy-chain-only antibodies in mice. Proc. Natl Acad. Sci. USA 103, 15130–15135 (2006).
doi: 10.1073/pnas.0601108103 pubmed: 17015837 pmcid: 1586177
Han, L., Masani, S. & Yu, K. Overlapping activation-induced cytidine deaminase hotspot motifs in Ig class-switch recombination. Proc. Natl Acad. Sci. USA 108, 11584–11589 (2011).
doi: 10.1073/pnas.1018726108 pubmed: 21709240 pmcid: 3136278
Achour, I. et al. Tetrameric and homodimeric camelid IgGs originate from the same IgH locus. J. Immunol. 181, 2001–2009 (2008).
doi: 10.4049/jimmunol.181.3.2001 pubmed: 18641337
The Bactrian Camels Genome Sequencing and Analysis Consortium. Genome sequences of wild and domestic bactrian camels. Nat. Commun. 3, 1202 (2012).
doi: 10.1038/ncomms2192
Wu, H. et al. Camelid genomes reveal evolution and adaptation to desert environments. Nat. Commun. 5, 5188 (2014).
doi: 10.1038/ncomms6188 pubmed: 25333821
Pardon, E. et al. A general protocol for the generation of nanobodies for structural biology. Nat. Protocols 9, 674–693 (2014).
doi: 10.1038/nprot.2014.039 pubmed: 24577359
Gaspar, J. M. NGmerge: merging paired-end reads via novel empirically-derived models of sequencing errors. BMC Bioinformatics 19, 536 (2018).
doi: 10.1186/s12859-018-2579-2 pubmed: 30572828 pmcid: 6302405
Zhang, X. et al. pTrimmer: an efficient tool to trim primers of multiplex deep sequencing data. BMC Bioinformatics 20, 236 (2019).
doi: 10.1186/s12859-019-2854-x pubmed: 31077131 pmcid: 6511130
Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884–i890 (2018).
doi: 10.1093/bioinformatics/bty560 pubmed: 30423086 pmcid: 6129281
Ye, J., Ma, N., Madden, T. L. & Ostell, J. M. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res. 41, W34–W40 (2013).
doi: 10.1093/nar/gkt382 pubmed: 23671333 pmcid: 3692102
Magoč, T. & Salzberg, S. L. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 27, 2957–2963 (2011).
doi: 10.1093/bioinformatics/btr507 pubmed: 21903629 pmcid: 3198573
Dunbar, J. & Deane, C. M. ANARCI: antigen receptor numbering and receptor classification. Bioinformatics 32, 298–300 (2016).
pubmed: 26424857
Li, W. & Godzik, A. Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics 22, 1658–1659 (2006).
doi: 10.1093/bioinformatics/btl158 pubmed: 16731699
Chuang, G. Y. et al. Structure-based design of a soluble prefusion-closed HIV-1 env trimer with reduced CD4 affinity and improved immunogenicity. J. Virol. 91, e02268-16 (2017).
doi: 10.1128/JVI.02268-16 pubmed: 28275193 pmcid: 5411596
Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033–1036 (2020).
doi: 10.1038/s41591-020-0913-5 pubmed: 32398876 pmcid: 8183627
Stadlbauer, D. et al. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr. Protoc. Microbiol. 57, e100 (2020).
doi: 10.1002/cpmc.100 pubmed: 32302069 pmcid: 7235504
Zhou, T. et al. Structure-based design with tag-based purification and in-process biotinylation enable streamlined development of SARS-CoV-2 spike molecular probes. Cell Rep. 33, 108322 (2020).
Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife 9, e61312 (2020).
doi: 10.7554/eLife.61312 pubmed: 33112236 pmcid: 7723407
Muecksch, F. et al. Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. Preprint at https://doi.org/10.1101/2021.03.07.434227 (2021).
Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450–456 (2020).
doi: 10.1038/s41586-020-2571-7 pubmed: 32698192
Wang, P. et al. SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerg. Microbes Infect. 9, 2091–2093 (2020).
doi: 10.1080/22221751.2020.1823890 pubmed: 32930052 pmcid: 7534308
Leem, J., Dunbar, J., Georges, G., Shi, J. & Deane, C. M. ABodyBuilder: automated antibody structure prediction with data-driven accuracy estimation. MAbs 8, 1259–1268 (2016).
doi: 10.1080/19420862.2016.1205773 pubmed: 27392298 pmcid: 5058620

Auteurs

Jianliang Xu (J)

Lymphocyte Nuclear Biology, NIAMS, NIH, Bethesda, MD, USA. jianliang.xu@nih.gov.
ORCID: 0000-0003-4154-4322

Kai Xu (K)

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.

Seolkyoung Jung (S)

Lymphocyte Nuclear Biology, NIAMS, NIH, Bethesda, MD, USA.

Andrea Conte (A)

Lymphocyte Nuclear Biology, NIAMS, NIH, Bethesda, MD, USA.

Jenna Lieberman (J)

Lymphocyte Nuclear Biology, NIAMS, NIH, Bethesda, MD, USA.

Frauke Muecksch (F)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0002-0132-5101

Julio Cesar Cetrulo Lorenzi (JCC)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0003-2492-3961

Solji Park (S)

Lymphocyte Nuclear Biology, NIAMS, NIH, Bethesda, MD, USA.

Fabian Schmidt (F)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.

Zijun Wang (Z)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.

Yaoxing Huang (Y)

Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
ORCID: 0000-0001-6270-1644

Yang Luo (Y)

Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.

Manoj S Nair (MS)

Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
ORCID: 0000-0002-5994-3957

Pengfei Wang (P)

Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.

Jonathan E Schulz (JE)

Laboratory of Virology, Division of Intramural Research, NIAID, NIH, Rocky Mountain Laboratories, Hamilton, MT, USA.

Lino Tessarollo (L)

Mouse Cancer Genetics Program, CCR, NCI, NIH, Frederick, MD, USA.

Tatsiana Bylund (T)

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.

Gwo-Yu Chuang (GY)

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.

Adam S Olia (AS)

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.

Tyler Stephens (T)

Electron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD, USA.

I-Ting Teng (IT)

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.

Yaroslav Tsybovsky (Y)

Electron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD, USA.

Tongqing Zhou (T)

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.

Vincent Munster (V)

Laboratory of Virology, Division of Intramural Research, NIAID, NIH, Rocky Mountain Laboratories, Hamilton, MT, USA.
ORCID: 0000-0002-2288-3196

David D Ho (DD)

Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
ORCID: 0000-0003-1627-149X

Theodora Hatziioannou (T)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0002-7889-0766

Paul D Bieniasz (PD)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA.
ORCID: 0000-0002-2368-3719

Michel C Nussenzweig (MC)

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. nussen@mail.rockefeller.edu.
Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA. nussen@mail.rockefeller.edu.
ORCID: 0000-0003-0592-8564

Peter D Kwong (PD)

Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA. pdkwong@nih.gov.
ORCID: 0000-0003-3560-232X

Rafael Casellas (R)

Lymphocyte Nuclear Biology, NIAMS, NIH, Bethesda, MD, USA. rafael.casellas@nih.gov.
The NIH Regulome Project, NIH, Bethesda, MD, USA. rafael.casellas@nih.gov.
Center for Cancer Research, NCI, NIH, Bethesda, MD, USA. rafael.casellas@nih.gov.
ORCID: 0000-0001-9282-2287

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Nanobodies from camelid mice and llamas...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Nanobodies from camelid mice and llamas...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Extinction de l'expression des gènes › Systèmes CRISPR-Cas › Nanobodies from camelid mice and llamas...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Artiodactyla › Camelidae › Camélidés du Nouveau Monde › Nanobodies from camelid mice and llamas...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Génie génétique › Édition de gène › Nanobodies from camelid mice and llamas...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Nanobodies from camelid mice and llamas...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Nanobodies from camelid mice and llamas...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Nanobodies from camelid mice and llamas...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles moléculaires › Nanobodies from camelid mice and llamas...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Nanobodies from camelid mice and llamas...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Tests immunologiques › Tests sérologiques › Tests de neutralisation › Nanobodies from camelid mice and llamas...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Nanobodies from camelid mice and llamas...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Fragments d'immunoglobuline › Fragments Fab d'immunoglobuline › Anticorps à domaine unique › Nanobodies from camelid mice and llamas...
questionsmedicales.fr › Phénomènes du système immunitaire › Phénomènes immunogénétiques › Hypermutation somatique des gènes des immunoglobulines › Nanobodies from camelid mice and llamas...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Protéines de fusion virale › Glycoprotéine de spicule des coronavirus › Nanobodies from camelid mice and llamas...